If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

FeedbackNow, the world leader in operational analytics for physical spaces, announced today their Series A round. The round was led by Motivate VC, Uncorrelated Ventures, and AI Growth Capital ...

Venturi Cardiology, a leading, state of the art cardiology clinic in North West England offering rapid access to clinical ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

GSK looks like it is starting to show the benefit ... as well as respiratory syncytial virus (RSV) vaccine Arexvy and myelofibrosis therapy Omjjara/Ojjaara (momelotinib) – both launched within ...